Compare DexCom, Inc. (DXCM) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? DexCom, Inc. trades at $76.99 (market cap $28.06B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.8. The key difference: DexCom, Inc. is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | HYG | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | Fixed Income |
52-Week High | $89.53 | $81.32 |
52-Week Low | $54.84 | $78.72 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
HYG trades at $79.785, up 0.13% with a bearish technical bias from moving averages, while oscillators are neutral. Recent dividends include H1-26 payments of $0.41 and $0.42, and H2-26 at $0.37. News highlights bond ETF inflows and rate hike speculation, with put volume spikes indicating bearish bets on high-yield bonds.
Outlook is cautious due to technical weakness and Fed uncertainty; opportunities exist from yield appeal, but risks include inflation-driven rate hikes and economic slowdowns pressuring corporate debt. Monitor earnings and Fed policy for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
